Rituximab (Ituxredi) - for the treatment of non-Hodgkin'slymphoma (NHL), chronic lymphocytic leukaemia (CLL), rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis and pemphigus vulgaris. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Ituxredi, intended for the treatment of non-Hodgkin’slymphoma (NHL), chronic lymphocytic leukaemia (CLL), rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis and pemphigus vulgaris. The applicant for this medicinal product is Reddy Holding GmbH
Non-Hodgkin'slymphoma Skip to main contentSkip to searchAbout usHelpSubscribeAccess through your institutionLog inBMJ Best PracticeSearchSearchSelect languageNon-Hodgkin's lymphoma MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:24 Apr 2023Last updated:23 May 2023SummaryNon-Hodgkin's lymphomas (NHLs) are a heterogeneous group of malignancies of the lymphoid
Rituximab (Mabthera or other brands) in certain non-Hodgkinlymphomas in children Prescrire IN ENGLISH - Spotlight ''In the February issue of Prescrire International: Rituximab (Mabthera° or other brands) in certain non-Hodgkinlymphomas in children'', 1 February 2022 {1}##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1}##LOC[OK]####LOC[Cancel]## Register online| Log in| My Prescrire Issue contents events * A global network Offers * Subscribe now * Solidarity Subscription Rate * Subscribers: register online * Prescrire's other products * Free Special Edition * Sign up to receive the newsletter english.prescrire.org > Spotlight > 100 most recent > In the February issue of Prescrire International: Rituximab (Mabthera° or other brands) in certain non-Hodgkinlymphomas in children
Mosunetuzumab axgb (Lunsumio) - To treat adults with relapsed or refractory follicular lymphoma, a type of non-Hodgkinlymphoma Skip to main contentSkip to FDA SearchSkip to footer links An official website of the United States government Here's how you know U.S. Food and Drug Administration Search MenuSearch FDASubmit search Home Drugs Drug Approvals and Databases Drugs@FDADrug Approval
Non-HodgkinLymphoma, Childhood Skip to main contentAn official website of the United States governmentEspañolMenuSearchHome Cancer Types Lymphoma Health Professional Childhood Non-HodgkinLymphoma Treatment (PDQ®)–Health Professional VersionPrintEmailChildhood Non-HodgkinLymphoma Treatment (PDQ®)–Health Professional VersionGo to Patient VersionON THIS PAGEGeneral Information About Childhood Non-HodgkinLymphoma (NHL)Histopathologic and Molecular Classification of Childhood NHLStage Information for Childhood NHLTreatment Option Overview for Childhood NHLSpecial Considerations for the Treatment of Children With CancerAggressive Mature B-cell NHLLymphoblastic LymphomaAnaplastic Large Cell LymphomaLymphoproliferative Disease Associated With Immunodeficiency in ChildrenRare NHL Occurring
Non-HodgkinLymphoma, Adult Skip to main contentAn official website of the United States governmentEspañolMenuSearchHome Cancer Types Lymphoma Health Professional Non-HodgkinLymphoma Treatment (PDQ®)–Health Professional VersionPrintEmailNon-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional VersionGo to Patient VersionON THIS PAGEGeneral Information About Non-HodgkinLymphoma (NHL)Late , Noncontiguous Stage II/III/IV NHLTreatment of Aggressive, Recurrent NHLTreatment of Lymphoblastic Lymphoma (LBL)/Acute Lymphocytic Leukemia (ALL)Treatment of Diffuse, Small Noncleaved-Cell/Burkitt LymphomaTreatment of NHL During PregnancyChanges to This Summary (02/17/2023)About This PDQ SummaryGeneral Information About Non-HodgkinLymphoma (NHL)In This SectionIncidence and MortalityAnatomyPrognosis
Allogeneic stem cell transplantation in aggressive B-cell non-Hodgkinlymphoma and in T-cell non-Hodgkinlymphoma 1 Translation of Chapters 1 to 6 of the final report N17-02 Allogene Stammzelltransplantation bei aggressiven B- Zell-Non-Hodgkin-Lymphomen und bei T- Zell-Non-Hodgkin-Lymphomen (Version 1.0; Status: 26 March 2019 [German original], 19 November 2019 [English translation]). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. N17-02 Allogeneic stem cell transplantation in aggressive B-cell non-Hodgkinlymphoma
Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkinlymphoma Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cells has emerged as a novel modality for treating relapsed and/or refractory B-cell non-Hodgkinlymphoma (B-NHL). With increasing approval of CAR T-cell products
Rituximab (Ruxience) - Non-Hodgkin'sLymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA) Search Page - Drug and Health Product Register * Skip to main content * Skip to "About this site"Language selection * FrançaisGovernment of CanadaSearch and menus * Search and menusSearchSearch websiteSearchTopics menu * Jobs * Immigration * Travel * Business * Benefits * Health
Rituximab (Riximyo) - Non?Hodgkin'sLymphoma, Chronic Lymphocytic Leukemia or Rheumatoid Arthritis Search Page - Drug and Health Product Register * Skip to main content * Skip to "About this site"Language selection * FrançaisGovernment of CanadaSearch and menus * Search and menusSearchSearch websiteSearchTopics menu * Jobs * Immigration * Travel * Business * Benefits * Health * Taxes * More
Rituximab for treating non-Hodgkin’slymphoma and chronic lymphocytic leukaemia ACE Technology Guidances A Singapore Government Agency Website SEARCH Who We Are Organisational Structure Advisory Committees Committees We Serve Careers at ACE Healthcare Professionals ACE Clinical Guidances (ACGs) ACE CUES ACE Technology Guidances ACE Horizon Scanning Patients & Community Asthma Resources Plain : * Rituximab biosimilar (Truxima) 100 mg/10 ml and 500 mg/50 ml concentrate for infusion for treating: * CD20-positive diffuse large B-cell non-Hodgkin’slymphoma, * Indolent B-cell non-Hodgkin’slymphomas
Somatic tumour gene testing for the diagnosis of diffuse large B cell lymphoma, multiple myeloma and non-Hodgkinlymphoma subtypes 1 Public Summary Document Application No. 1526 – Somatic gene testing of haematological malignancies Applicant: The Royal College of Pathologists of Australasia (RCPA) Date of MSAC consideration: MSAC 76th Meeting, 1-2 August 2019 Context for decision: MSAC makes , per the application form Category 6 –Genetics P7 Detection of gene rearrangements in MYC, BCL2 and BCL6 in a patient with Diffuse Large B Cell Lymphoma or high-grade B-cell lymphoma OR Identification of the following genetic abnormalities in Non-HodgkinLymphoma: • MYC gene rearrangement for the diagnosis of Burkitt Lymphoma, AND/OR • one or more of CCND1 and CCND2 gene rearrangements
Carmustine (Carmustine Obvius) as conditioning treatment before transplantation in patients with Hodgkin’s lymphoma (HL) and non-Hodgkin’slymphomas (NHL) Carmustine (Carmustine Obvius®) as conditioning treatment before transplantation in patients with Hodgkin’s lymphoma (HL) and non-Hodgkin’slymphomas (NHL) - Repository of AIHTA GmbH English | Deutsch Atom RSS 1.0 RSS 2.0 * Simple search * Advanced search * Help * Services * Login * Browse * Type * Subject * Author / Editor * Institution * YearAIHTA - Publications - Search - Carmustine (Carmustine Obvius®) as conditioning treatment before transplantation in patients with Hodgkin’s lymphoma (HL) and non-Hodgkin’slymphomas (NHL) Grössmann, N.(2020):Carmustine (Carmustine Obvius®) as conditioning treatment before transplantation in patients
Non-Hodgkin'slymphomaNon-Hodgkin'slymphoma - Symptoms, diagnosis and treatment | BMJ Best PracticeSkip to main contentSkip to search * About us * Help * Subscribe * Access through your institution * Log inBMJ Best Practice * Help * Getting started * FAQs * Contact us * Recent updates * Specialties * Calculators * Patient leaflets * Videos * Evidence * Drugs * Recent updates for 21 days) is the most commonly used chemotherapy regimen.DefinitionNon-Hodgkin's lymphomas (NHL) are a heterogeneous group of malignancies of the lymphoid system.[1]Armitage JO. Treatment of non-Hodgkin'slymphoma. N Engl J Med. 1993 Apr 8;328(14):1023-30.http://www.ncbi.nlm.nih.gov/pubmed/8450856?tool=bestpractice.com This heterogeneity (>30 entities) stems from the functions of the lymphoid arm
Improving outcomes of childhood and young adult non-Hodgkinlymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-HodgkinLymphoma. The European Intergroup for Childhood Non-HodgkinLymphoma (EICNHL) was established 25 years ago with the goal to facilitate clinical trials and research collaborations in the field both within Europe and worldwide. Since its inception, much progress has been made whereby major improvements in outcomes have been achieved. In this Review, we describe the different diagnostic entities of non-Hodgkinlymphoma in children and young adults describing key features of each entity and outlining clinical achievements made in the context of the EICNHL framework. Furthermore, we provide an overview of advances
International validation of two EORTC questionnaires for assessment of health-related quality of life for patients with high-grade non-Hodgkinlymphoma (QLQ-NHL-HG29) and low-grade non-Hodgkinlymphoma (QLQ-NHL-LG20). Health-related quality of life (HRQOL) is a critical aspect to consider when making treatment decisions for patients with non-Hodgkin-lymphoma (NHL). This international study Group developed two questionnaires. These questionnaires measure health-related quality of life. The questionnaires are for patients with high-grade or low-grade non-Hodgkinlymphoma. They are called the EORTC QLQ-NHL-HG29 and QLQ-NHL-LG20. The questionnaires are now internationally validated. This study demonstrates that the questionnaires are reliably and valid, which are important aspects
B-cell non-Hodgkinlymphomas. B-cell lymphomas occur with an incidence of 20 new cases per 100 000 people per year in high-income countries. They can affect any organ and are characterised by heterogeneous clinical presentations and courses, varying from asymptomatic, to indolent, to very aggressive cases. Since the topic of B-cell non-Hodgkinlymphomas was last reviewed in The Lancet in 2017 , a deeper understanding of the biological background of this heterogeneous group of malignancies, the availability of new diagnostic methods, and the development and implementation of new targeted and immunotherapeutic approaches have improved our ability to treat patients. This Seminar provides an overview of the pathobiology, classification, and prognostication of B-cell non-Hodgkinlymphomas
Investigation of occupational risk factors for the development of non-Hodgkin'slymphoma in adults: A hospital-based case-control study. Non-Hodgkin'sLymphoma (NHL) is a malignancy of the lymphoid lineage of the hematopoietic system has worldwide, especially in developed countries. Better diagnostic and recording techniques, longer life expectancy, and greater exposure to risk factors
Incidence and survival of second primary non-Hodgkinlymphoma: A Surveillance, Epidemiology, and End Results-based cohort study. The aim of this study was to investigate patient survival and factors associated with survival in second primary non-Hodgkinlymphoma (NHL) compared with the first primary NHL. The retrospective cohort study used data from the Surveillance, Epidemiology, and End